This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sidiropoulos, P I Articles by Boumpas, D T Search for Related Content PubMed PubMed Citation Articles by Sidiropoulos, P I Articles by Boumpas, D T Social Bookmarking                   What's this?

Lupus nephritis flares

Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece

H D Kritikos

Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece

D T Boumpas

Rheumatology, Clinical Immunology and Allergy, University Hospital, Medical School, University of Crete, Heraklion, Greece, boumpasd{at}med.uoc.gr

The clinical course of lupus nephritis varies remarkably among SLE patients, even between those with the same histological type. Current immunosuppressive agents induce remission in the majority of the patients with proliferative lupus nephritis, but a substantial proportion of them - ranging in different studies from 27% to 66% - will flare. Flares represent a significant problem because of the potential for cumulative damage that may lead to deterioration of renal function as well as toxicity due to the additional immunosuppression. Maintenance therapy with azathioprine, mycophenolate mofetil or quarterly pulses of cyclophosphamide is usually recommended. Renal flares can be characterized as nephritic or nephrotic and can be mild or severe. The majority of the patients that flare restore renal function, if diagnosed early and treated promptly. However, current immunosuppressive agents have limitations concerning efficacy and toxicity profiles. Unresolved management issues include the value of repeat renal biopsy and issues related to optimal strategy/regimen to prevent flares. Renal flares are an important feature of the natural history of lupus nephritis and provide an opportunity for additional preventive strategies, as well as measures of efficacy in future therapeutic trials.

Key Words: corticosteroids • flare • immunosuppression • lupus nephritis

Lupus, Vol. 14, No. 1, 49-52 (2005)
DOI: 10.1191/0961203305lu2059oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]

				C. Grootscholten and J. H. M. Berden Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1465 - 1469. [Full Text] [PDF]

				M.-T. Tseng, S.-C. Hsieh, C.-T. Shun, K.-L. Lee, C.-L. Pan, W.-M. Lin, Y.-H. Lin, C.-L. Yu, and S.-T. Hsieh Skin denervation and cutaneous vasculitis in systemic lupus erythematosus Brain, April 1, 2006; 129(4): 977 - 985. [Abstract] [Full Text] [PDF]